Antiva Biosciences

Redwood City, CA · Founded 2012 · CIK 0001563355 · Biotech · Private

Topical therapies for HPV-induced pre-cancerous lesions

antivabio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$81M
8 Form D · May 2023
41 months since last filing
Contracts
—
No federal contracts on record
Patents
15
1 granted · 14 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$501,006
Private capital raisedForm D · SEC$1,100,000
Private capital raisedForm D · SEC$1,745,019
Private capital raisedForm D · SEC$8,907,483
Private capital raisedForm D · SEC$11,140,756
Private capital raisedForm D · SEC$15,000,000
Private capital raisedForm D · SEC$15,639,364
Private capital raisedForm D · SEC$26,565,771
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2394EXARCA PHARMACEUTICALS, LLC——
2395Translate Bio—$98M
2396NeuvaRx, LLC——
2397Antiva Biosciences—$81M
2398Fate Therapeutics—$236M
2399COLORADO RESEARCH PARTNERS, LLC——
2400Halda Therapeutics—$198M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 26 related persons
  • Kristine BallDirector · Executive Officer
  • Keith BleyExecutive Officer
  • Michael CannonDirector
  • Elaine ChienExecutive Officer
  • Oranee DanielsExecutive Officer
  • Raju GadirajuExecutive Officer
  • Raju Gadiraju, Ph.D.Executive Officer
  • Brian GoodmanDirector
  • Karl HostetlerDirector · Executive Officer
  • Wende HuttonDirector
  • Wendee HuttonDirector
  • Steven JamesDirector
  • Ting JiaDirector
  • David KabakoffDirector
  • David Kabakoff, Ph.D.Director
  • Gail MaderisDirector · Executive Officer
  • Vinzenz PloererDirector
  • William RespessDirector
  • Beni RovinskiDirector
  • Benjamin RovinskiDirector
  • Clifford SamuelDirector
  • John SaywardExecutive Officer
  • Florencia SegalDirector
  • Michael SullivanExecutive Officer
  • Sarah WalterExecutive Officer
  • Jenny YipDirector

Patents

USPTO · 1 granted of 15
  • Compositions and Dosage Forms for Treatment of HPV Infection and HPV-Induced Neoplasiaapplication
  • Compositions And Dosage Forms For Treatment Of Hpv Infection And Hpv-induced Neoplasiagranted
  • Treatment Of Hpv Infectionapplication
  • Treatment Of Hpv-induced Neoplasiaapplication
  • Synthesis Of ETHYL-2-((((2-(2-AMINO-6-METHOXY-9H-PURIN-9-YL)-ETHOXY)-METHYL)-(BENZYLOXY)-PHOSPHORYL)-AMINO)-PROPIONATEapplication
  • Advantageous Compounds For Treatment Of Hpv Infection And Hpv-induced Neoplasiaapplication
  • Device System And Use For Hpv Infection And Cervical Intraepithelial Neoplasiaapplication
  • Device System And Use For Hpv Infection And Cervical Intraepithelial Neoplasiaapplication
  • Compositions And Dosage Forms For Treatment Of Hpv Infection And Hpv-induced Neoplasiaapplication
  • Compositions And Dosage Forms For Treatment Of Hpv Infection And Hpv-induced Neoplasiaapplication
  • Compositions And Dosage Forms For Treatment Of Hpv Infection And Hpv-induced Neoplasiaapplication
  • Compositions And Dosage Forms For Treatment Of Hpv Infection And Hpv-induced Neoplasiaapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.